Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

What Was Tested

In this phase 4 trial, researchers set out to test Tirzepatide.

This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity.

There will be monthly check-ins to monitor progress and safety.

It had 1 arm (groups): Drug (experimental).

The registry classes the interventions as drug.

Who Took Part

30 planned participants were the target.

It was open to women only aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age ≥ 18. Obesity as defined by current BMI ≥ 30 kg/m² or ≥ 27.5 kg/m² for individuals of Asian ancestry. Postmenopausal as defined by one or more of the following. Age ≥60 years. Age \<60 years with amenorrhea for ≥ 1 year.

The full record lists 12 inclusion and 10 exclusion criteria; among the exclusions: stage iv breast cancer; concomitant use of cdk inhibitors; concomitant use of antiher2 therapy.

How the Study Was Run

Design: single-group and open-label.

Everyone knew when Tirzepatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2026-06-08 with completion listed for 2027-12-03.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Percentage of participants completing week 24 visit with all required assessments (time frame: 24 weeks).

It also tracked 19 secondary outcomes, for example Percent change in body weight from baseline to week 24, Absolute change in visceral fat mass from baseline to week 24, Percent change in visceral fat mass from baseline to week 24, Absolute change in fasting glucose from baseline to week 24, Percent change in fasting glucose from baseline to week 24 and Absolute change in fasting insulin from baseline to week 24.

What This Means in Plain Language

Put simply, this is a phase 4 trial of Tirzepatide in 30 people.

Its size is small, so on its own it can only give an early look.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, all human trials.